178 related articles for article (PubMed ID: 33393702)
1. Expanded utilization of rituximab in paediatric cardiac transplant patients.
Kiskaddon AL; Landmesser K; Carapellucci J; Wisotzkey B; Asante-Korang A
J Clin Pharm Ther; 2021 Jun; 46(3):762-766. PubMed ID: 33393702
[TBL] [Abstract][Full Text] [Related]
2. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
Mahadeo KM; Baiocchi R; Beitinjaneh A; Chaganti S; Choquet S; Dierickx D; Dinavahi R; Duan X; Gamelin L; Ghobadi A; Guzman-Becerra N; Joshi M; Mehta A; Navarro WH; Nikiforow S; O'Reilly RJ; Reshef R; Ruiz F; Spindler T; Prockop S
Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune haemolytic anaemia associated with Epstein Barr virus infection as a severe late complication after kidney transplantation and successful treatment with rituximab: case report.
Hamilton AJ; Webb LH; Williams JK; D'Souza RJ; Ngu LS; Moore J
BMC Nephrol; 2015 Jul; 16():108. PubMed ID: 26187383
[TBL] [Abstract][Full Text] [Related]
4. Treatment and outcomes of immune cytopenias following solid organ transplant in children.
Schoettler M; Elisofon SA; Kim HB; Blume ED; Rodig N; Boyer D; Neufeld EJ; Grace RF
Pediatr Blood Cancer; 2015 Feb; 62(2):214-218. PubMed ID: 25308853
[TBL] [Abstract][Full Text] [Related]
5. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Ohto H; Kikuta A
Pediatr Int; 2017 Sep; 59(9):973-978. PubMed ID: 28581032
[TBL] [Abstract][Full Text] [Related]
6. Maintenence rituximab following induction in autoimmune cytopenias.
Rai MP; Lee EJ; Bussel JB
Br J Haematol; 2023 Jul; 202(1):153-158. PubMed ID: 37086173
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura in pediatric solid organ transplant recipients, report of five cases and review of the literature.
Miloh T; Arnon R; Roman E; Hurlet A; Kerkar N; Wistinghausen B
Pediatr Transplant; 2011 Dec; 15(8):870-8. PubMed ID: 22112003
[TBL] [Abstract][Full Text] [Related]
8. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.
Schachtner T; Reinke P
Transpl Infect Dis; 2016 Dec; 18(6):881-888. PubMed ID: 27632022
[TBL] [Abstract][Full Text] [Related]
12. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
Olfat M; Silverman ED; Levy DM
Lupus; 2015 Aug; 24(9):966-72. PubMed ID: 25804672
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
14. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.
Gómez-Almaguer D; Solano-Genesta M; Tarín-Arzaga L; Herrera-Garza JL; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Jaime-Pérez JC
Blood; 2010 Dec; 116(23):4783-5. PubMed ID: 20841509
[TBL] [Abstract][Full Text] [Related]
15. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
Provan D; Butler T; Evangelista ML; Amadori S; Newland AC; Stasi R
Haematologica; 2007 Dec; 92(12):1695-8. PubMed ID: 18055995
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia.
Aleem A
Ann Saudi Med; 2008; 28(5):382-5. PubMed ID: 18779631
[No Abstract] [Full Text] [Related]
18. [The effectiveness of rituximab in refractory autoimmune thrombocytopenic purpura and haemolytic anaemia].
Martínez Velasco E; Gómez Castillo JJ; Fernández Megía MJ; González Joga B; Barreda Hernández D; Gómez Roncero MI
Farm Hosp; 2007; 31(2):124-7. PubMed ID: 17590122
[TBL] [Abstract][Full Text] [Related]
19. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.
Raj K; Narayanan S; Augustson B; Ho A; Mehta P; Duncan N; Tauro S; Mahendra P; Craddock C; Mufti G
Bone Marrow Transplant; 2005 Feb; 35(3):299-301. PubMed ID: 15568036
[TBL] [Abstract][Full Text] [Related]
20. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
